{"id":46,"date":"2008-10-30T13:59:30","date_gmt":"2008-10-30T12:59:30","guid":{"rendered":"http:\/\/localhost\/new\/htb\/?p=46"},"modified":"2013-08-23T13:37:51","modified_gmt":"2013-08-23T13:37:51","slug":"atripla-to-be-licensed-in-latin-america-and-the-asia-pacific-region","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/46","title":{"rendered":"Atripla to be licensed in Latin America and the Asia-Pacific region"},"content":{"rendered":"<p><strong>On 1 August 2008, a press release from Gilead Sciences announced that Atripla (the fixed-dose combination table of efavirenz plus Truvada) will be licensed and distributed to in 12 countries located primarily in Latin America and the Asia-Pacific region: Argentina, Australia, Chile, Hong Kong, Israel, Mexico, New Zealand, Russia, Taiwan, Thailand, Turkey and Uruguay. Gilead will assume the lead role in these countries.<\/strong><\/p>\n<p>138 countries are now covered under agreements between Gilead and Merck or Bristol-Myers Squibb. In August 2006, Gilead and Merck entered into an agreement under which Merck distributes Atripla at substantially discounted pricing in 94 developing nations, including nations in sub-Saharan Africa.<\/p>\n<p>Source: Merck and Gilead press release: Gilead Sciences and Merck &amp; Co enter into an agreement to register and distribute Atripla in twelve countries, including in Latin America and the Asia-Pacific region. (1 August 2008)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>On 1 August 2008, a press release from Gilead Sciences announced that Atripla (the fixed-dose combination table of efavirenz plus Truvada) will be licensed and distributed to in 12 countries located primarily in Latin America and the Asia-Pacific region: Argentina, &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[38],"tags":[],"class_list":["post-46","post","type-post","status-publish","format-standard","hentry","category-treatment-access"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/46","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=46"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/46\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=46"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=46"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=46"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}